News
URGN
--
0.00%
--
Idaho Champion Gold Mobilizes Second Core Rig to Champagne Project
Second Drill to Focus on New Target Areas Outside Past Producing PitTORONTO, ON / ACCESSWIRE / October 27, 2020 / Idaho Champion Gold Mines Canada Inc.
ACCESSWIRE · 18h ago
We Think UroGen Pharma (NASDAQ:URGN) Needs To Drive Business Growth Carefully
Simply Wall St. · 10/07 17:58
Oppenheimer: 3 Stocks That Could Surge Over 100% From Current Levels
So far, September has been a wild ride of ups and downs. Following the recent bout of volatility, stocks have ticked higher again. But as uncertainty regarding another rescue program and the presidential election continues to linger, where does the market go from here? Weighing in for Oppenheimer, Chief
TipRanks · 09/15 17:14
UroGen Pharma Announces September 2020 Conference Schedule
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that it will present at the following virtual conferences in September:
Business Wire · 09/10 12:00
UroGen Pharma Expands Executive Team to Accelerate Platform Innovation and Drive Commercial Growth
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the appointment of three new executives to the Company's Executive Leadership Team (ELT). These new hires, all
Business Wire · 09/09 12:00
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced the grants of inducement restricted stock units ("RSUs") to nineteen new employees
Business Wire · 09/04 12:00
BeiGene COVID-19 Deal And Other News: The Good, Bad And Ugly Of Biopharma
BeiGene signs deal with Singlomics for neutralizing COVID-19 antibodies.UroGen flunks Phase 2 RTGel combo study.Matinas BioPharma reports progress for ENHANCE-IT study.
Seekingalpha · 08/30 08:22
UroGen's Phase 2 RTGel combo study for OAB misses primary endpoint
UroGen (URGN) -3.8% in premarket, says Phase 2 trial of RTGel hydrogel formulation in combination with Botox did not meet the primary endpoint of improvement of overactive bladder ((OAB)) symptoms, as measured
Seekingalpha · 08/27 12:59
UroGen Pharma Announces Update On Phase 2 Trial Of RTGel Hydrogel Formulation In Combination With BOTOX Intravesical Instillation For Overactive Bladder, Urinary Incontinence; Trial Did Not Meet Primary Endpoint
UroGen Pharma Announces Update on the Phase 2 Trial of an RTGel™ Hydrogel Formulation in Combination with BOTOX® (onabotulinumtoxinA) Intravesical Instillation for Overactive Bladder and Urinary
Benzinga · 08/27 12:22
Oncology Stocks Area Trading Materially Lower The Last 2 Months
Seeking Alpha - Article · 08/24 12:00
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 08/10 17:24
UroGen Pharma Q2 EPS $(1.44) Beats $(1.58) Estimate, Sales $372.00K Beat $260.00K Estimate
UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(1.44) per share which beat the analyst consensus estimate of $(1.58) by 8.86 percent. This is a 33.33 percent decrease over losses of $(1.08) per share from the
Benzinga · 08/10 12:14
UroGen Pharma to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020
UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases, today announced that it will report second quarter 2020 financial results on Monday, August 10, 2020, prior
Business Wire · 08/03 12:00
Hedge Funds Are Selling UroGen Pharma Ltd. (URGN)
Insider Monkey · 06/16 01:43
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · 06/05 13:00
UroGen Pharma (URGN) Presents At Jefferies Healthcare Conference - Slideshow
Seeking Alpha - Article · 06/03 22:13
UroGen Pharma to Present at Jefferies Virtual Healthcare Conference
Business Wire · 06/01 13:00
Cassava Slumped Last Week After Bad Data, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 05/19 19:12
UroGen Pharma Announces First Presentation of Data from Phase 2b Study of UGN-102 in Patients with Difficult to Treat Type of Bladder Cancer
Business Wire · 05/15 14:01
UroGen Announces Positive Data from Pivotal OLYMPUS Trial Evaluating Jelmyto in Patients with Low-Grade Upper Tract Urothelial Cancer
Business Wire · 05/15 14:00
Webull provides a variety of real-time URGN stock news. You can receive the latest news about Urogen Pharma through multiple platforms. This information may help you make smarter investment decisions.
About URGN
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidates include Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). Its platform technologies include: RTGel and Immunotherapy.
More